MMP-9 as predictive factor for response and progression free survival in breast cancer patients treated with bevacizumab and pegylated liposomal doxorubicin. A multicenter, single-arm phase II trial (SAKK24/06). On behalf of the Swiss Group for Clinical Cancer Research (SAKK).

Details

Ressource 1Download: BIB_140190B7EDBB.P001.pdf (1731.14 [Ko])
State: Public
Version: author
Serval ID
serval:BIB_140190B7EDBB
Type
Inproceedings: an article in a conference proceedings.
Publication sub-type
Poster: Summary – with images – on one page of the results of a researche project. The summaries of the poster must be entered in "Abstract" and not "Poster".
Collection
Publications
Institution
Title
MMP-9 as predictive factor for response and progression free survival in breast cancer patients treated with bevacizumab and pegylated liposomal doxorubicin. A multicenter, single-arm phase II trial (SAKK24/06). On behalf of the Swiss Group for Clinical Cancer Research (SAKK).
Title of the conference
33rd Annual San Antonio Breast Cancer Symposium
Author(s)
Zaman K., Rochlitz C., Ruhstaller T., Thürlimann B., Aebi S., Von Moos R., Mamot C., Gabriel N., Rossier-Pansier L., Stupp R., Crowe S., Ruegg C.
Address
San Antonio, United-States, December 8-10, 2010
Publication state
Published
Issued date
2010
Language
english
Abstract
The benefit of bevacizumab (Bv) has been shown in different tumors including colorectal cancer, renal cancer, pulmonary non-small cell cancer and also breast cancer. However to date, there is no established test evaluating the angiogenic status of a patient and monitoring the effects of anti-angiogenic treatments.
Tumor angiogenesis is the result of a balance between multiple pro- and anti¬angiogenic molecules. There is very little published clinical data exploring the impact of the anti-angiogenic therapy on the different angiogenesis-related molecules and the potential role of these molecules as prognostic or predictive factors.
Create date
22/02/2011 9:49
Last modification date
20/08/2019 12:42
Usage data